BLOOD AND MARROW TRANSPLANTATION ACTIVITY IN EUROPE 1995

In 1995, a total of 12101 blood or marrow transplants, performed in Eu rope by 343 teams from 31 countries, were reported to the European Gro up for Blood and Marrow Transplantation (EBMT), Of these, 3858 (32%) w ere allogeneic, 8243 (68%) autologous transplants, Of the autologous t ransplants 1384 (17%) were bone marrow derived, 6504 (79%) from periph eral blood stem cells and 355 (4%) combined bone marrow and peripheral blood stem cell transplants, Of the allogeneic transplants, 571 (15%) were peripheral blood stem cell transplants, the remainder, 3287 (85% ) bone marrow transplants, Main indications were leukemias with 4408 t ransplants (36%), 2977 allogeneic (68%) and 1431 autologous (32%); lym phomas with 4671 transplants (39%), 272 allogeneic (6%) and 4399 autol ogous (94%); severe aplastic anemia with 237 transplants (2%), 237 all ogeneic (100%) and 0 autologous (0%); solid tumors with 2399 transplan ts (20%), 17 allogeneic (1%) and 2382 autologous (99%); and congenital disorders with 294 transplants (2%), 294 allogeneic (100%) and 0 auto logous (0%) and others with 92 transplants (1%), 61 allogeneic (66%) a nd 31 autologous (34%), There were major differences between participa ting countries, The absolute numbers of teams and transplants per coun try differ widely and range from 0.2 to 33.3 teams per 10 million inha bitants (median 5.8); 3.2 to 733.3 total transplants per 10 million (m edian 200); 0.7 to 210 allogeneic transplants per 10 million (median 6 5); 0.3 to 700 autologous transplants per 10 million (median 122); 0 t o 47.7 unrelated transplants per 10 million inhabitants (median 8.7). There is also a difference in the relative number of transplants for t he individual indications, The coefficient of variation for selected d iseases was calculated for those 14 countries with a minimum of 100 tr ansplants, A narrow coefficient of variation indicates consensus among st grafting physicians, It is narrowest for chronic myeloid leukemia i n allogeneic transplants (36.7%) and for Hodgkin's disease in autologo us transplants (44.8%), These data reflect the present status of blood and marrow transplantation in Europe and provide a basis for patient counselling and health care planning.